LHDX: Lucira Health, Inc. - Summary | Jitta

Lucira Health, Inc.

NASDAQ:LHDX

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.00
Loss Chance
58.0%
1.60JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (20)
Recent Business Performance (56)
Financial Strength (30)
Return to Shareholders (0)
Competitive Advantage (26)
Jitta Signs
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 475.82% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
1.60
100.00%
3.06
159.47%
Health Care Equipment
4.57
185.66%
3.72
37.28%
7.50
2.19%
COMPANY DESCRIPTION
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California. On February 22, 2023, Lucira Health, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.